Literature DB >> 29903867

Btk inhibitors in atherosclerosis.

Jonathan R Lindner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29903867      PMCID： PMC6032894          DOI： 10.1182/blood-2018-04-841916

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Molecular Imaging of Platelet-Endothelial Interactions and Endothelial von Willebrand Factor in Early and Mid-Stage Atherosclerosis.

Authors:  Chi Young Shim; Ya Ni Liu; Tamara Atkinson; Aris Xie; Ted Foster; Brian P Davidson; Mackenzie Treible; Yue Qi; José A López; Adam Munday; Zaverio Ruggeri; Jonathan R Lindner
Journal:  Circ Cardiovasc Imaging       Date:  2015-07       Impact factor: 7.792

Review 2.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 3.  Flow shear stress and atherosclerosis: a matter of site specificity.

Authors:  Patrizia Nigro; Jun-Ichi Abe; Bradford C Berk
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

4.  Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

Authors:  S Kamel; L Horton; L Ysebaert; M Levade; K Burbury; S Tan; M Cole-Sinclair; J Reynolds; R Filshie; S Schischka; A Khot; S Sandhu; M J Keating; H Nandurkar; C S Tam
Journal:  Leukemia       Date:  2014-08-20       Impact factor: 11.528

5.  Atherothrombosis and the role of antiplatelet therapy.

Authors:  Ph G Steg; S H Dorman; P Amarenco
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 6.  Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage.

Authors:  Renu Virmani; Frank D Kolodgie; Allen P Burke; Aloke V Finn; Herman K Gold; Thomas N Tulenko; Steven P Wrenn; Jagat Narula
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-21       Impact factor: 8.311

7.  Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.

Authors:  Kristina Busygina; Janina Jamasbi; Till Seiler; Hans Deckmyn; Christian Weber; Richard Brandl; Reinhard Lorenz; Wolfgang Siess
Journal:  Blood       Date:  2018-03-20       Impact factor: 22.113

8.  A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

Authors:  L S Quek; J Bolen; S P Watson
Journal:  Curr Biol       Date:  1998-10-08       Impact factor: 10.834

9.  Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Authors:  Jennifer R Brown; Javid Moslehi; Susan O'Brien; Paolo Ghia; Peter Hillmen; Florence Cymbalista; Tait D Shanafelt; Graeme Fraser; Simon Rule; Thomas J Kipps; Steven Coutre; Marie-Sarah Dilhuydy; Paula Cramer; Alessandra Tedeschi; Ulrich Jaeger; Martin Dreyling; John C Byrd; Angela Howes; Michael Todd; Jessica Vermeulen; Danelle F James; Fong Clow; Lori Styles; Rudy Valentino; Mark Wildgust; Michelle Mahler; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

10.  A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo.

Authors:  Steffen Massberg; Meinrad Gawaz; Sabine Grüner; Valerie Schulte; Ildiko Konrad; Dietlind Zohlnhöfer; Ulrich Heinzmann; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307
  10 in total
  1 in total

Review 1.  Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease.

Authors:  Zeyu Yin; Yuanming Zou; Dong Wang; Xinyue Huang; Shengjun Xiong; Liu Cao; Ying Zhang; Yingxian Sun; Naijin Zhang
Journal:  Cell Death Discov       Date:  2022-03-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.